Keeps Biopharma Past Earnings Performance
Past criteria checks 0/6
Keeps Biopharma has been growing earnings at an average annual rate of 23.6%, while the Semiconductor industry saw earnings growing at 4.5% annually. Revenues have been growing at an average rate of 59.3% per year.
Key information
23.57%
Earnings growth rate
25.54%
EPS growth rate
| Semiconductor Industry Growth | 23.50% |
| Revenue growth rate | 59.32% |
| Return on equity | -0.84% |
| Net Margin | -0.84% |
| Last Earnings Update | 30 Jun 2025 |
Recent past performance updates
Recent updates
Is Keeps Biopharma (KOSDAQ:256940) Using Too Much Debt?
Sep 06
Not Many Are Piling Into Keeps Biopharma Inc. (KOSDAQ:256940) Stock Yet As It Plummets 27%
Aug 01Market Participants Recognise Keeps Biopharma Inc.'s (KOSDAQ:256940) Revenues Pushing Shares 43% Higher
Jun 17Is Keeps Biopharma (KOSDAQ:256940) A Risky Investment?
May 15Further Upside For Keeps Biopharma Inc. (KOSDAQ:256940) Shares Could Introduce Price Risks After 33% Bounce
Apr 18A Piece Of The Puzzle Missing From KPS Corporation's (KOSDAQ:256940) 33% Share Price Climb
Feb 06KPS (KOSDAQ:256940) Takes On Some Risk With Its Use Of Debt
Jan 13A Piece Of The Puzzle Missing From KPS Corporation's (KOSDAQ:256940) Share Price
Dec 06KPS (KOSDAQ:256940) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Mar 31Sentiment Still Eluding KPS Corporation (KOSDAQ:256940)
Feb 26Revenue & Expenses Breakdown
How Keeps Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 25 | 148,356 | -1,241 | 21,077 | 1,472 |
| 31 Mar 25 | 136,521 | -7,288 | 14,190 | 1,246 |
| 31 Dec 24 | 127,583 | 1,113 | 8,570 | 801 |
| 30 Sep 24 | 125,763 | 6,885 | 7,320 | 875 |
| 30 Jun 24 | 118,517 | 8,324 | 6,662 | 1,072 |
| 31 Mar 24 | 113,335 | 12,385 | 7,224 | 1,242 |
| 31 Dec 23 | 92,133 | 3,930 | 7,372 | 1,450 |
| 30 Sep 23 | 65,750 | -10,878 | 9,870 | 1,584 |
| 30 Jun 23 | 47,685 | -10,706 | 9,347 | 1,627 |
| 31 Mar 23 | 23,939 | -11,235 | 8,710 | 1,661 |
| 31 Dec 22 | 14,617 | -11,375 | 7,289 | 2,164 |
| 30 Sep 22 | 12,256 | -12,354 | 7,968 | 3,208 |
| 30 Jun 22 | 6,852 | -13,971 | 7,799 | 3,494 |
| 31 Mar 22 | 4,997 | -15,632 | 8,134 | 3,425 |
| 31 Dec 21 | 4,261 | -15,317 | 8,401 | 2,810 |
| 30 Sep 21 | 5,888 | -6,343 | 4,160 | 1,593 |
| 30 Jun 21 | 11,440 | -7,112 | 4,199 | 1,028 |
| 31 Mar 21 | 11,345 | -5,030 | 3,365 | 874 |
| 31 Dec 20 | 15,217 | -2,406 | 3,172 | 830 |
| 30 Sep 20 | 12,719 | -3,671 | 3,333 | 801 |
| 30 Jun 20 | 8,331 | -1,162 | 3,068 | 839 |
| 31 Mar 20 | 10,004 | -545 | 3,458 | 834 |
| 31 Dec 19 | 14,191 | -346 | 3,444 | 780 |
| 30 Sep 19 | 29,314 | 3,973 | 4,262 | 785 |
| 30 Jun 19 | 44,083 | 7,156 | 5,204 | 725 |
| 31 Mar 19 | 46,473 | 8,108 | 5,027 | 631 |
| 31 Dec 18 | 40,628 | 6,807 | 4,953 | 604 |
| 30 Sep 18 | 29,198 | 3,334 | 4,653 | 557 |
| 30 Jun 18 | 17,194 | 227 | 4,336 | 515 |
| 31 Dec 17 | 24,043 | 2,193 | 4,318 | 355 |
Quality Earnings: A256940 is currently unprofitable.
Growing Profit Margin: A256940 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A256940 is unprofitable, but has reduced losses over the past 5 years at a rate of 23.6% per year.
Accelerating Growth: Unable to compare A256940's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A256940 is unprofitable, making it difficult to compare its past year earnings growth to the Semiconductor industry (13.7%).
Return on Equity
High ROE: A256940 has a negative Return on Equity (-0.84%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 08:49 |
| End of Day Share Price | 2025/10/02 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Keeps Biopharma Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dong Hee Han | Kiwoom Securities Co., Ltd. |
| YoungSik Yoon | Shinhan Investment Corp. |
| Sun-Jae Heo | SK Securities Co., Ltd. |